GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

In recent years, the U.K.-listed pharma giant has called increasingly on U.S. law firms for its transactional work.

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...

Discover the details about Andrew Witty’s life, such as his educational qualifications, career graph, major achievements, ...

With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...

Nearly six months after late UnitedHealthcare CEO, Brian Thompson, was fatally shot, UnitedHealth Group’s CEO, Andrew Witty, ...

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses ...

Quarterly Net Profit at Rs. 262.87 crore in March 2025 up 35.17% from Rs. 194.48 crore in March 2024. EBITDA stands at Rs. 373.87 crore in March 2025 up 30.23% from Rs. 287.09 crore in March 2024.

India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its ...

The head of UnitedHealth Group is stepping down, ending a rocky four years marked by rising medical costs, a major ...